Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:RYTM 11 December 2025 - 30 December 2025

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals shares dropped 4.2% to $107.85 in early afternoon trading Tuesday as biotech stocks broadly declined. Investors are awaiting an FDA decision on expanding Imcivree’s label, now expected by March 20, 2026. Board member Camille L. Bedrosian resigned effective immediately, according to an SEC filing. Major biotech ETFs fell over 1% while the broader market was flat.
30 December 2025
··
Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals shares jumped over 15% to a record high near $121 on December 11 after reporting positive interim Phase 2 data for setmelanotide in Prader-Willi syndrome. Six of eight patients showed BMI reductions at three months, and most saw declines in hunger scores. The company plans a Phase 3 trial pending Phase 2 completion. RYTM stock is up around 80–90% year-to-date.
11 December 2025
·

Stock Market Today

  • Russell 2000 Hits Correction Territory Amid Oil Price Surge and Economic Worries
    March 20, 2026, 2:58 PM EDT. The Russell 2000 small-cap index has dropped over 10% from its recent peak, marking the first major U.S. benchmark to enter correction territory, defined as a decline between 10% and 20%. The index, initially outperforming in 2026, fell sharply due to a surge in Brent crude oil prices amid the Iran war, highlighting small caps' sensitivity to cyclical sectors and economic downturns. Other major indexes are close behind, with the Dow and Nasdaq down over 9%, and the S&P 500 falling by more than 6%, signaling broader market pressures.
Go toTop